Efficacy and Safety of Remimazolam Compared to Midazolam for Sedation During Endoscopic Ultrasonography: A Single‐Center Retrospective Cohort Study
DEN Open · 2026-04 · 6 (1)
DOI: 10.1002/deo2.70267 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift DEN Open, online erschienen am 04.02.2026. Verfasst von Haruka Toyonaga und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology Kansai Medical University Medical Center Osaka Japan. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Remimazolam is a novel ultra–short‐acting benzodiazepine that may offer advantages over conventional sedatives in endoscopic procedures. Evidence for its use in pancreatobiliary endoscopic ultrasonography (EUS) is limited. We compared the efficacy and safety of remimazolam and midazolam in outpatient pancreatobiliary EUS.
Methods
This retrospective study included outpatients undergoing diagnostic pancreatobiliary EUS between July 2024 and July 2025. Patients received either remimazolam (initial 0.2 mg/kg, top‐up 0.1 mg/kg [high‐risk patients: 0.16 mg/kg, 0.08 mg/kg]) or midazolam. The target sedation depth was Modified Observer's Assessment of Alertness/Sedation ≤3, procedures were performed without supplemental oxygen, and pentazocine was co‐administered. The primary outcome was rapid recovery (meeting all criteria: modified Aldrete score ≥6 at 5 min, ≥9 at 30 min, ambulation ≥3 m at 30 min). Secondary outcomes included sedation success (all: EUS completion, without >2 top‐ups within 10 min, without rescue sedation, without agitation requiring interruption), recovery time, flumazenil use, and adverse events.
Results
We analyzed 139 patients (remimazolam, n = 75; midazolam, n = 64). Rapid recovery was more frequent with remimazolam (70.7% vs. 25.0%, p < 0.001). Sedation success was higher (92.0% vs. 73.4%, p = 0.005), recovery was shorter (median 34 vs. 55 min, p < 0.001), and flumazenil use was lower (4.0% vs. 45.3%, p < 0.001). Hypoxemia (SpO 2
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology Kansai Medical University Medical Center Osaka Japan.
- Department of Community Medicine Section of Clinical Epidemiology Graduate School of Medicine Kyoto University Kyoto Japan.
- Third Department of Internal Medicine Division of Gastroenterology and Hepatology Kansai Medical University Hospital Osaka Japan.
ORCID-Profile: Haruka Toyonaga, Makoto Masaki
Zitieren
APA
Toyonaga, H., Masaki, M., Yamazaki, H., Oka, A., Matsuno, Y., Nakata, H., Takayama, S., Nakagawa, T., Takayama, T., Orino, M., Matsumoto, H., Sumimoto, K., Takeo, M., Fukata, N., Yamashina, T., Shimatani, M., & Naganuma, M. (2026). Efficacy and Safety of Remimazolam Compared to Midazolam for Sedation During Endoscopic Ultrasonography: A Single‐Center Retrospective Cohort Study. DEN Open, 6(1). https://doi.org/10.1002/deo2.70267
Vancouver
Toyonaga H, Masaki M, Yamazaki H, Oka A, Matsuno Y, Nakata H, et al. Efficacy and Safety of Remimazolam Compared to Midazolam for Sedation During Endoscopic Ultrasonography: A Single‐Center Retrospective Cohort Study. DEN Open. 2026;6(1). doi:10.1002/deo2.70267
BibTeX
@article{Toyonaga2026,
author = {Toyonaga, Haruka and Masaki, Makoto and Yamazaki, Hajime and Oka, Arata and Matsuno, Yoshiki and Nakata, Hidetoshi and Takayama, Shoji and Nakagawa, Tatsuya and Takayama, Takuya and Orino, Masahiro and Matsumoto, Hironao and Sumimoto, Kimi and Takeo, Masahiro and Fukata, Norimasa and Yamashina, Takeshi and Shimatani, Masaaki and Naganuma, Makoto},
title = {Efficacy and Safety of Remimazolam Compared to Midazolam for Sedation During Endoscopic Ultrasonography: A Single‐Center Retrospective Cohort Study},
journal = {DEN Open},
year = {2026},
volume = {6},
number = {1},
doi = {10.1002/deo2.70267}
}
EUVIMED